Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ki23819 |
| Synonyms | |
| Therapy Description |
Ki23819 inhibits both wild-type FLT3 and FLT3 containing activating internal tandem duplications, which may block downstream signaling and induce apoptosis in cancer cells (PMID: 15815726). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ki23819 | FLT3 Inhibitor 69 | Ki23819 inhibits both wild-type FLT3 and FLT3 containing activating internal tandem duplications, which may block downstream signaling and induce apoptosis in cancer cells (PMID: 15815726). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Ki23819 | Preclinical - Cell culture | Actionable | In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication were sensitive to Ki23819 in culture, demonstrating inhibition of autophosphorylation and downstream signaling, and reduced cell proliferation (PMID: 15815726). | 15815726 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|